The Financial Times: Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate
Scientists at UC say restoring a brain protein, not removing amyloid plaques, should be the target
The debate over a new drug to treat Alzheimer's is still going strong, with many experts rebutting the science behind its recent FDA approval. One of the most vocal voices objecting to the new drug is UC's Alberto Espay, MD.
“The FDA approval will stimulate further investments into a hypothesis that should have long ago been falsified,” Espay told The Finanical Times.
Espay and a team of researchers at UC and the Karolinska Institute in Sweden back his position with their recent, and highly publicized study, pointing to a different target for the treatment of Alzheimer's disease.
Read The Financial Times article, which has been reprinted in several international news outlets, includinh Kenya News.
Read more about Espay and the UC-led study.
Featured image at top of Alberto Espay, MD. Photo/Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
Local 12: Head injury survivor, doctor share importance of...
April 23, 2024
Local 12 spoke with patient Shane Shapiro and the University of Cincinnati's Laura Ngwenya about the importance of wearing a helmet following Shapiro's traumatic brain injury and recovery.
WVXU: Why is part of Green Township called Dent?
April 23, 2024
UC College of Arts and Sciences professor tells WVXU that Ohio's glacial past might explain how Dent got its name.
UC hires Dr. Gregory Postel as senior vice president of health...
April 23, 2024
UC Board of Trustees vote to hire Dr. Gregory Postel as senior vice president of health affairs and dean of UC College of Medicine.